0001654954-26-003936
SEC filingAstraZeneca PLC announced FDA approval of Saphnelo (anifrolumab) as a once-weekly subcutaneous autoinjector (Saphnelo Pen) for systemic lupus erythematosus in the US, expanding patient access beyond existing IV infusion and supporting broader commercial reach in a growing autoimmune franchise.
This regulatory milestone significantly advances AstraZeneca’s Respiratory & Immunology franchise by converting Saphnelo from a clinic-administered IV therapy into a patient-accessible self-injectable option in the US — the world’s largest pharmaceutical market. The Saphnelo Pen approval directly addresses key unmet needs in systemic lupus erythematosus: convenience, treatment flexibility, and reduced reliance on healthcare infrastructure. With SLE affecting over 3.4 million people globally and carrying high risks of irreversible organ damage — particularly linked to long-term corticosteroid use — the ability to achieve low disease activity and remission (as demonstrated in TULIP-SC and TULIP-LTE) strengthens Saphnelo’s clinical differentiation. The approval builds on established global adoption (>40,000 treated patients) and extends geographic alignment: subcutaneous administration is already approved in the EU and Japan, and under active review elsewhere. Financially, the arrangement with BMS — a mid-teens royalty on US sales under a 2025 update to the original 2004 license — confirms continued commercialization rights while preserving margin structure. Strategically, this expands AstraZeneca’s footprint in immune-mediated diseases beyond oncology and rare diseases, reinforcing its commitment to delivering life-changing medicines in chronic, debilitating conditions. Ongoing Phase III trials in cutaneous lupus, myositis, systemic sclerosis, and lupus nephritis further signal pipeline momentum around the type I interferon pathway.